GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Milei Threatens Falkland Oil Firms With Sanctions 
Anthropic IPO Marketing Expected to Start in Mid-October 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Add as a preferred source on Google
MORRISTOWN, N.J., Feb. 22, 2018 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the fourth quarter and fiscal year ended December 31, 2017, after the market close on Thursday, March 8, 2018. Pernix management will also host a conference call at 4:30pm Eastern Time to discuss the results.
| Date: | Thursday, March 8 | |
| Time: | 4:30 PM ET | |
| Toll free (U.S.): | 888-882-4478 | |
| International: | 323-794-2149 | |
| Conference ID: | 4931261 | |
| Webcast: | http://public.viavid.com/index.php?id=128364 |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company is currently focused on the therapeutic areas of Pain and Neurology, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its internal sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT
Investor Relations
Bob Yedid
LifeSci Advisors, LLC
[email protected]
